Wegovy oral tablets: the UK's first oral GLP-1 weight-loss medicine

Step 1, what you are actually taking, and why it works differently from the injection

Wegovy tablets contain semaglutide combined with an absorption enhancer called SNAC. Semaglutide activates GLP-1 receptors in the gut and brain, slowing the rate at which the stomach empties and signalling fullness earlier in a meal. The GLP-1 pathway is also present in the injection, so the biological effect on appetite and blood sugar is closely related, the meaningful difference is delivery route, not mechanism.

The SNAC component is what makes oral absorption possible. Semaglutide on its own would be broken down before it reached the bloodstream, so SNAC temporarily adjusts the local stomach environment to allow the molecule through. That chemical handshake is why the tablet must be taken in a specific way: first thing in the morning, on an empty stomach, swallowed whole with a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before any food, coffee or other oral medicines. The tablet can't do its job if it competes with breakfast or a morning cup of tea. Worth building into your routine early.

Rybelsus (which is also oral semaglutide) uses the same SNAC technology but carries different doses (3 mg, 7 mg, 14 mg) and is licensed only for type 2 diabetes. Those strengths are not steps in the Wegovy tablets weight-loss ladder, and the products are not interchangeable. The Wegovy pill overview has more on how the two products relate.

Step 2, the dose schedule and how clinical review fits into each increase

Treatment begins at 1.5 mg daily. After a minimum of one month, a prescriber can move you to 4 mg, then 9 mg, then 25 mg, the maintenance dose. There is no shortcut through those steps; the escalation exists to let your body adjust and to keep side effects manageable.

If you are already established on the 2.4 mg weekly injection, your prescriber may be able to start you directly on the 25 mg tablet, subject to clinical assessment. That transition is not automatic and should never be self-managed. For more on how oral Wegovy and injectable semaglutide compare, the semaglutide oral tablets guide covers the practical differences in one place.

At every dose increase, a clinical re-review matters. Side effects (primarily nausea, loose stools and indigestion) tend to be most noticeable in the first days after moving up. In the OASIS 4 trial, gastrointestinal effects were reported by around 74% of participants taking the tablet versus 42% in the placebo group. Most were mild to moderate and settled over time. If symptoms are severe or persistent, contact your prescriber rather than adjusting the dose independently. The nume FAQs page covers what to do if you have questions between reviews.

Step 3, reading the trial results honestly

The phase 3 OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks, with lifestyle support alongside treatment. The headline result was around 13.6% average weight loss compared with roughly 2.4% on placebo. Among participants who adhered fully throughout the trial, the average was closer to 17%, a meaningful difference, and one that matters when you read that figure quoted elsewhere.

Neither figure is a prediction for any individual. Weight loss depends on starting point, how well the dose is tolerated, dietary changes, and other health factors. The MHRA's published approvals for semaglutide give the regulatory context, while the NHS semaglutide medicines page covers side effects and safety information in plain language. A prescriber's job is to put those numbers in the context of your own health.

One practical note: because the Wegovy oral tablet does not require a cold chain, the treatment arrives ready to store in a drawer or medicine cabinet rather than a refrigerator. Patients who travel frequently, or who simply found managing a cold-stored pen cumbersome, often find this a genuine advantage. That said, the clinical question of which form of semaglutide (or which treatment altogether) suits you is one for a prescriber, not a comparison article. The weight-loss treatments overview sets out the landscape if you are still deciding.

Step 4, who can be prescribed Wegovy tablets, and how to access them

The licence covers adults with a BMI of 30 or above, or those with a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. That is the licensed threshold; BMI alone does not guarantee a prescription. A prescriber weighs your full medical history, any medicines you currently take, and conditions that might make treatment inadvisable.

Wegovy tablets are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They are not licensed for under-18s. If you use daily oral contraceptives, discuss this with your prescriber: guidance for the injectable form of tirzepatide notes that GLP-1 medicines can affect how quickly oral medicines are absorbed, the same caution is worth raising for the tablet.

Wegovy tablets are available by private prescription only; a NICE appraisal would be needed before NHS commissioning. At the moment, this is a private route. You can explore whether oral semaglutide might be right for you through our semaglutide tablet consultation page, or review all treatment options at the consultation hub, where a GPhC-registered prescriber reviews every application the same day it is submitted. There is no subscription and no obligation, the consultation itself is free.